May 12, 2022 / 03:40PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Good morning. Welcome to the third day of the Bank of America Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. And we're honored to have BioMarin Pharmaceuticals here on stage with us. And speaking on behalf of BioMarin is Chairman and CEO, JJ Bienaime; and also Brian Mueller, CFO.
So guys, welcome. Good to do face-to-face. So I guess, JJ, just give us a few minutes of prepared kind of a background, and then we'll get right into some questions.
Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO
So I will make some very brief introductory comments. So thank you for having us, Geoff. It's a pleasure to be here. So we recently reported our first quarter financials. So we're off to a very good start for the year. Obviously, all eyes are on the VOXZOGO launch, which is our first full quarter since we were approved in Europe and the U.S. in Q4 of last year. Actually, we really launched it
Biomarin Pharmaceutical Inc at Bank of America Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers